Patient preference often leans towards GLP-1 receptor agonists that require less frequent doses or come in oral forms due to convenience factors
Retatrutide activates three receptors (GLP-1, GIP, and glucagon) compared to Semaglutides single GLP-1 agonism and Tirzepatides dual GLP-1/GIP agonism
Besides, oxygen provision is deficient on account of hypertrophic adipose tissue and hypoxia is associated with fatty infiltration caused by M1 M, which may be a potential mechanism of IR (122, 124)
Retatrutide produced 28.7% body weight loss at 68 weeks in Phase 3 trials
For individuals with IBS-D, the slowing effect may provide a welcomed sense of regularity
By acting on these three hormones, retatrutide is designed to reduce both how much you eat and how much energy your body burns